A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

Alan Breier, Karena Meehan, Martin Birkett, Stacy David, Iris Ferchland, Virginia Sutton, Cindy C. Taylor, Rebecca Palmer, Martin Dossenbach, Geri Kiesler, Shlomo Brook, Padraig Wright

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Background: An intramuscular (IM) formulation of olanzapine has been developed because there are no rapidacting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia. Methods: Recently hospitalized acutely agitated patients with schizophrenia (N = 270) were randomized to receive 1 to 3 IM injections of olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), or placebo within 24 hours. A dose-response relationship for 1M olanzapine in the reduction of agitation was assessed by measuring the reduction in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores 2 hours after the first injection. Safety was assessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at 24 hours after the first injection. Results: Olanzapine exhibited a dose-response relationship for reduction in agitation (F1,179=14.4; P

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalArchives of General Psychiatry
Volume59
Issue number5
StatePublished - 2002

Fingerprint

olanzapine
Haloperidol
Schizophrenia
Placebos
Injections
Intramuscular Injections
Therapeutics
Antipsychotic Agents
Electrocardiography
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. / Breier, Alan; Meehan, Karena; Birkett, Martin; David, Stacy; Ferchland, Iris; Sutton, Virginia; Taylor, Cindy C.; Palmer, Rebecca; Dossenbach, Martin; Kiesler, Geri; Brook, Shlomo; Wright, Padraig.

In: Archives of General Psychiatry, Vol. 59, No. 5, 2002, p. 441-448.

Research output: Contribution to journalArticle

Breier, A, Meehan, K, Birkett, M, David, S, Ferchland, I, Sutton, V, Taylor, CC, Palmer, R, Dossenbach, M, Kiesler, G, Brook, S & Wright, P 2002, 'A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia', Archives of General Psychiatry, vol. 59, no. 5, pp. 441-448.
Breier, Alan ; Meehan, Karena ; Birkett, Martin ; David, Stacy ; Ferchland, Iris ; Sutton, Virginia ; Taylor, Cindy C. ; Palmer, Rebecca ; Dossenbach, Martin ; Kiesler, Geri ; Brook, Shlomo ; Wright, Padraig. / A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. In: Archives of General Psychiatry. 2002 ; Vol. 59, No. 5. pp. 441-448.
@article{950c775acab342caa12a6f7e6b7fd1f7,
title = "A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia",
abstract = "Background: An intramuscular (IM) formulation of olanzapine has been developed because there are no rapidacting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia. Methods: Recently hospitalized acutely agitated patients with schizophrenia (N = 270) were randomized to receive 1 to 3 IM injections of olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), or placebo within 24 hours. A dose-response relationship for 1M olanzapine in the reduction of agitation was assessed by measuring the reduction in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores 2 hours after the first injection. Safety was assessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at 24 hours after the first injection. Results: Olanzapine exhibited a dose-response relationship for reduction in agitation (F1,179=14.4; P",
author = "Alan Breier and Karena Meehan and Martin Birkett and Stacy David and Iris Ferchland and Virginia Sutton and Taylor, {Cindy C.} and Rebecca Palmer and Martin Dossenbach and Geri Kiesler and Shlomo Brook and Padraig Wright",
year = "2002",
language = "English (US)",
volume = "59",
pages = "441--448",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

AU - Breier, Alan

AU - Meehan, Karena

AU - Birkett, Martin

AU - David, Stacy

AU - Ferchland, Iris

AU - Sutton, Virginia

AU - Taylor, Cindy C.

AU - Palmer, Rebecca

AU - Dossenbach, Martin

AU - Kiesler, Geri

AU - Brook, Shlomo

AU - Wright, Padraig

PY - 2002

Y1 - 2002

N2 - Background: An intramuscular (IM) formulation of olanzapine has been developed because there are no rapidacting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia. Methods: Recently hospitalized acutely agitated patients with schizophrenia (N = 270) were randomized to receive 1 to 3 IM injections of olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), or placebo within 24 hours. A dose-response relationship for 1M olanzapine in the reduction of agitation was assessed by measuring the reduction in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores 2 hours after the first injection. Safety was assessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at 24 hours after the first injection. Results: Olanzapine exhibited a dose-response relationship for reduction in agitation (F1,179=14.4; P

AB - Background: An intramuscular (IM) formulation of olanzapine has been developed because there are no rapidacting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia. Methods: Recently hospitalized acutely agitated patients with schizophrenia (N = 270) were randomized to receive 1 to 3 IM injections of olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), or placebo within 24 hours. A dose-response relationship for 1M olanzapine in the reduction of agitation was assessed by measuring the reduction in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores 2 hours after the first injection. Safety was assessed by recording adverse events and with extrapyramidal symptom scales and electrocardiograms at 24 hours after the first injection. Results: Olanzapine exhibited a dose-response relationship for reduction in agitation (F1,179=14.4; P

UR - http://www.scopus.com/inward/record.url?scp=0036244492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036244492&partnerID=8YFLogxK

M3 - Article

C2 - 11982448

AN - SCOPUS:0036244492

VL - 59

SP - 441

EP - 448

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 5

ER -